2374
document
Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma . We evaluated the focal therapeutic effect of oily carcinostatic agents administered by transcatheter arterial infusion ( TAI ) as the initial therapy in patients with hepatocellular carcinoma in a randomized controlled clinical trial . Group A ( 19 patients ) received 4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol , and group B ( 18 patients ) received 100 mg of epirubicin in 4 ml of Lipiodol via the tumor feeding arteries as peripherally as possible . The grade of Lipiodol accumulation and the tumor regression rate were determined 2 weeks after TAI by computerized tomography . Adverse effects within 2 weeks after TAI were evaluated by subjective signs and symptoms such as fever ( maximum body temperature ) and the frequency of shaking chills and abdominal pain , and by biochemical parameters such as albumin , prothrombin time , and aspartate and alanine aminotransferases . Lipiodol accumulation in the tumor was significantly greater in group A ( 12/19 ; 63.2 % showing grade IV Lipiodol accumulation ) than in group B ( 3/18 ; 16.7 % showing grade IV ) ( P < 0.05 ) . The tumor regression rate was also significantly greater in group A ( 8/17 ; 47.1 % showing more than 25 % tumor regression ) than in group B ( 1/13 ; 7.7 % showing more than 25 % tumor regression ) ( P < 0.05 ) . Although clinically significant elevations of aminotransferases and reductions of cholinesterase , and shaking chills were observed more often in group A than in group B ( P < 0.0001 ) , these factors had little influence on the clinical outcome . Our results suggest that styrene maleic acid neocarzinostatin in Lipiodol exerts a more favorable focal therapeutic effect than does epirubicin in Lipiodol in the initial treatment of hepatocellular carcinoma .
2375
Intervention_Pharmacological
styrene maleic acid
2376
Intervention_Pharmacological
oily carcinostatic agents
2377
Intervention_Pharmacological
4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol
2378
Intervention_Pharmacological
100 mg of epirubicin in 4 ml of Lipiodol
2379
Intervention_Pharmacological
styrene maleic acid neocarzinostatin
2380
Intervention_Pharmacological
epirubicin
2381
Intervention_Pharmacological
Lipiodol
2382
Outcome_Other
Focal therapeutic efficacy
2383
Outcome_Other
focal therapeutic effect
2384
Outcome_Adverse-effects
fever ( maximum body temperature )
2385
Outcome_Physical
frequency of shaking chills
2386
Outcome_Adverse-effects
abdominal pain
2387
Outcome_Physical
Lipiodol accumulation in the tumor
2388
Outcome_Physical
tumor regression rate
2389
Outcome_Physical
elevations of aminotransferases
2390
Outcome_Physical
reductions of cholinesterase
2391
Outcome_Physical
shaking chills
2392
Outcome_Other
more favorable focal therapeutic effect
2393
Participant_Condition
patients with hepatocellular carcinoma
2394
Participant_Sample-size
Group A ( 19 patients
2395
Participant_Condition
)
2396
Participant_Sample-size
group B ( 18 patients )